Liquid biopsy–based detection of the patient-specific TERT rearrangement breakpoints mirror the presence of disease in individual patients, indicating the potential for this assay to monitor disease in patients with high-risk and very high-risk neuroblastomas harboring TERT rearrangements. This evidence concerns the gene TERT and neuroblastoma.